REZOLVE-AA trial

Class action lawsuit filed against $NKTX alleging executives made false statements about REZOLVE-AA trial integrity. Investors urged to join by May 5, 2026 deadline.

Nektar Therapeutics faces securities lawsuit over REZOLVE-AA trial enrollment irregularities. Eligible investors have until May 5, 2026 to pursue compensation.

Class action lawsuit filed against Nektar Therapeutics alleging executives made false statements about REZOLVE-AA trial enrollment, claiming protocol violations negatively impacted results.

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.

Class action lawsuit filed against Nektar Therapeutics alleging materially false statements regarding REZOLVE-AA trial enrollment protocols, claiming compromised trial integrity.

Nektar faces securities litigation over alleged misstatements about REZOLVE-AA trial enrollment practices. Stock fell 7.77% after trial failure announcement.

Rosen Law Firm files securities class actions against Nektar Therapeutics, Enphase Energy, and Aquestive Therapeutics. Investors have until May 5, 2026 to join.

Class action lawsuit filed against $NKTX alleging executives made false statements about REZOLVE-AA trial enrollment protocols, potentially harming investor value.

Nektar Therapeutics faces securities class action over alleged misstatements about REZOLVE-AA trial, with stock falling 7.77% after trial failure announcement.

Schall Law Firm launches class action against $NKTR for alleged securities fraud tied to REZOLVE-AA trial protocol violations and misstatements between February-December 2025.

Schall Law Firm seeks investors in class action against $NKTR over alleged false statements regarding REZOLVE-AA trial enrollment and integrity.